Income Statement (TTM)
Q32 Bio Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
2022 12-31 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
|
---|---|---|---|---|---|---|
Revenue | 7 | 12 | -7 | -10 | -13 | -15 |
Change (%) | 77.28 | -156.41 | 44.31 | 33.39 | 14.52 | |
% of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
Cost Of Sales | 36 | 33 | 32 | 24 | 16 | 23 |
Change (%) | -9.03 | -2.61 | -24.44 | -31.83 | 42.11 | |
% of Revenue | 538.48 | 276.31 | -477.06 | -249.80 | -127.67 | -158.42 |
Gross Operating Profit | -29 | -21 | -38 | -34 | -29 | -38 |
Change (%) | -28.71 | 84.62 | -12.52 | -13.18 | 29.99 | |
% of Revenue | -438.48 | -176.31 | 577.06 | 349.80 | 227.67 | 258.42 |
SG&A | 10 | 10 | 10 | 12 | 15 | 17 |
Change (%) | -4.91 | 3.21 | 26.25 | 16.40 | 15.67 | |
% of Revenue | 151.29 | 81.15 | -148.47 | -129.89 | -113.35 | -114.49 |
R&D | 10 | 23 | 23 | |||
Change (%) | 134.50 | 0.00 | ||||
% of Revenue | -100.90 | -177.37 | -154.88 | |||
OpEx | 46 | 42 | 42 | 46 | 54 | 63 |
Change (%) | -8.13 | -1.29 | 10.87 | 16.13 | 17.09 | |
% of Revenue | 689.76 | 357.46 | -625.53 | -480.59 | -418.39 | -427.79 |
Operating Income | -39 | -30 | -48 | -56 | -66 | -77 |
Change (%) | -22.61 | 58.96 | 15.48 | 19.10 | 16.60 | |
% of Revenue | -589.76 | -257.46 | 725.53 | 580.59 | 518.39 | 527.79 |
Interest Expense | -2 | -2 | -2 | -2 | ||
Change (%) | -0.00 | -0.00 | 15.00 | |||
% of Revenue | 30.07 | 20.84 | 15.62 | 15.69 | ||
Net Income | -43 | -36 | -54 | -46 | -57 | -61 |
Change (%) | -15.06 | 47.79 | -14.64 | 24.35 | 6.25 | |
% of Revenue | -643.65 | -308.40 | 808.04 | 477.97 | 445.58 | 413.39 |
Source: Capital IQ